Waverley Pharma Inc.
WAVE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.20K | 107.40K | 218.00K | 305.70K | 402.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.20K | 107.40K | 218.00K | 305.70K | 402.00K |
| Cost of Revenue | 77.40K | 125.00K | 159.60K | 246.00K | 282.20K |
| Gross Profit | -25.20K | -17.50K | 58.50K | 59.80K | 119.90K |
| SG&A Expenses | 520.50K | 650.90K | 752.90K | 835.40K | 798.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 172.90K |
| Total Operating Expenses | 940.80K | 1.04M | 1.09M | 1.26M | 1.43M |
| Operating Income | -888.50K | -930.50K | -876.30K | -949.40K | -1.02M |
| Income Before Tax | -1.63M | -1.66M | -1.59M | -1.64M | -814.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.63 | -1.66 | -1.59 | -1.64 | -0.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.63M | -1.66M | -1.59M | -1.64M | -814.20K |
| EBIT | -888.50K | -930.50K | -876.30K | -949.40K | -1.02M |
| EBITDA | -710.10K | -692.90K | -637.60K | -710.90K | -785.40K |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.04 | -0.04 | -0.03 | -0.04 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 216.00M | 216.00M | 216.00M | 216.00M | 216.00M |
| Average Diluted Shares Outstanding | 216.00M | 216.00M | 216.00M | 216.00M | 216.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |